Skip to main content

Table 2 Characteristics of the subjects according to eGFR levels

From: Albuminuria but not low eGFR is closely associated with atherosclerosis in patients with type 2 diabetes: an observational study

Variables

eGFR ≥ 90ml/min/1.73m2 (n = 1684)

eGFR 60–89 ml/min/1.73m2 (n = 719)

eGFR < 60ml/min/1.73m2 (n = 162)

p value

p* value

Male (n, %)

930 (55.2%)

410 (57.0%)

88 (54.3%)

0.674

< 0.001

Age (years)

56 ± 12

66 ± 10

69 ± 10

< 0.001

< 0.001

DD (months)*

72 (12–120)

96 (36–156)

120 (60–192)

< 0.001

0.234

Hypertension (n, %)

788 (46.8%)

456 (63.4%)

132 (81.5%)

< 0.001

< 0.001

Drinking (n, %)

287 (17.0%)

100 (13.9%)

10 (6.2%)

< 0.001

0.025

Smoking (n, %)

520 (30.9%)

185 (25.7%)

33 (20.4%)

0.002

0.358

APA (n, %)

789 (46.9%)

436 (60.6%)

92 (56.8%)

< 0.001

0.066

LLD (n, %)

509 (30.2%)

234 (32.5%)

56 (34.6%)

0.332

0.093

AHA (n, %)

700 (41.6%)

434 (60.4%)

126 (77.8%)

< 0.001

< 0.001

IIA (n, %)

1209 (71.8%)

491 (68.3%)

146 (90.1%)

< 0.001

< 0.001

Metformin (n, %)

993 (59.0%)

378 (52.6%)

73 (45.1%)

< 0.001

0.016

Insulin sensitizers (n,%)

258 (15.3%)

97 (13.5%)

22 (13.6%)

0.464

0.642

SBP (mmHg)

130 ± 17

134 ± 18

141 ± 21

< 0.001

< 0.001

DBP (mmHg)

80 ± 10

80 ± 10

80 ± 11

< 0.001

0.918

WC (cm)

88.62 ± 10.24

90.25 ± 10.32

92.51 ± 9.67

< 0.001

< 0.001

WHR

0.91 ± 0.06

0.91 ± 0.07

0.93 ± 0.06

< 0.001

0.009

BMI (kg/m2)

24.7 ± 3.48

25.13 ± 3.21

25.74 ± 3.69

< 0.001

< 0.001

FPG (mmol/l)*

8.07 (6.48–10.04)

7.27 (5.9-9)

7.06 (5.62–8.89)

< 0.001

< 0.001

2-h PPG (mmol/l)*

13.81 (10.51–17.17)

13.14 (9.66–16.49)

12.15 (9.58–16.94)

0.005

0.137

HbA1c (%)

9.34 ± 2.34

8.79 ± 2.29

8.81 ± 2.69

0.150

< 0.001

FCP (ng/mL)*

1.58 (0.94–2.33)

1.7 (1.1–2.53)

2.21 (1.2–3.58)

< 0.001

< 0.001

2-h PCP (ng/mL)*

3.46 (1.88–5.18)

4.12 (2.43–5.53)

4.18 (2.32–5.82)

< 0.001

< 0.001

HOMA2-IR*

1.4 (0.8-2)

1.4 (0.9–2.1)

2 (0.9–2.9)

0.050

< 0.001

TG (mmol/l)*

1.43 (0.99–2.14)

1.42 (1–2.03)

1.55 (1.08–2.39)

0.512

< 0.001

TC (mmol/l)

4.73 ± 1.1

4.67 ± 1.08

4.97 ± 1.45

< 0.001

0.001

HDL-C (mmol/l)

1.12 ± 0.3

1.11 ± 0.3

1.06 ± 0.3

< 0.001

< 0.001

LDL-C (mmol/l)

3.14 ± 0.95

3.07 ± 0.93

3.2 ± 1.08

< 0.001

0.251

ALT (U/l)*

20 (14–31)

19 (13–27)

16 (12–26)

0.006

0.607

SUA (µmol/l) *

292 (244–351)

330 (278–391)

414 (349–495)

< 0.001

< 0.001

  1. Values are expressed as the mean ± S.D, or median with interquartile range, or percentages
  2. eGFR estimated glomerular filtration rate, DD duration of diabetes, APA anti-platelet agents, LLD lipid-lowering drugs, AHA anti-hypertensive agents, IIA insulin or insulin analogue, SBP systolic blood pressure, DBP diastolic blood pressure, WC waist circumference, WHR waist-to-hip ratio, BMI body mass index, FPG fasting plasma glucose, 2-h PPG 2-h postprandial plasma glucose, HbA1c glycated hemoglobin A1c, FCP fasting C-peptide, 2-h PCP 2-h postprandial C-peptide, HOMA2-IR HOMA of insulin resistance, TG total triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, ALT alanine transaminase, SUA serum uric acid
  3. p value: The p-values were not adjusted for sex and age for the trend
  4. p* value: The p-values were adjusted for sex and age for the trend
  5. * The Kruskal-Wallis test was applied
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us